Uncategorized
The Exciting Research That May Cure Parkinsons
Parkinson’s disease is on the rise. According to the World Health Organization, the prevalence of the neurodegenerative disease has doubled worldwide since the turn of the century. Is there anything we can do about it? Read more about prof. Saarma’s research and GeneCode’s mission here: https://www.freethink.com/health/the-exciting-research-that-may-cure-parkinsons
Read MoreGeneCode selected among the most promising pharma companies in the European Union
GeneCode selected among the most promising biotech companies in the European Union. Read press release
Read MoreGenecode set to expand our GDNF Mimetics Platform
At GeneCode, we’re thrilled to share a major milestone in our research journey. With the recent €1.6M grant from Enterprise Estonia (EAS), we are set to expand our GDNF Mimetics Platform to address ALS, Retinitis Pigmentosa, and Inflammatory Bowel Disease. Read more
Read MoreTop 5 Best BioTech Companies to Watch
GeneCode has been named one of the TOP 5 best biotech companies to watch in 2024 by The Silicon Review! GeneCode research group led by Prof. Dr. Saarma is investigating the structure, biology, and therapeutic potential of neurotrophic factors. We specifically study the GDNF family neurotrophic factors and their receptors. Prof. Dr. Saarma’s exclusive interview is available…
Read MoreTOP10 Drug Discovery and Development Solutions Provider in Europe 2023
The Life Sciences Review has nominated GeneCode Ltd. among TOP10 Drug Discovery and Development Solutions Provider in Europe 2023. GeneCode Reprint (PDF) GeneCode Ltd | Top Drug Discovery and Development Solutions Company in Europe-2023 (lifesciencesreview.com)
Read MoreGeneCode – Enterprise Estonia
GeneCode’s R&D project has received tremendous backing from Enterprise Estonia, and we are grateful for their critical support. In collaboration with them, we have taken time to reflect on our journey with them and Argobio and look ahead to the future. https://investinestonia.com/follow-the-science-end-up-in-estonia/
Read MoreEuropean Innovation Council (EIC) Accelerator
European Innovation Council (EIC) Accelerator is providing € 16 million to support the development of a drug and treatment to slow the progression in Parkinson’s disease. The funding to GeneCode for the Kevad Bio project developed in collaboration with Argobio is split into a € 1.7 million grant and € 14.3 million in equity investments. This…
Read MoreLaunch of WHO’s Parkinson disease technical brief
Launch of WHO’s Parkinson disease technical brief. Globally, the prevalence of Parkinson disease (PD) has doubled in the past 25 years with global estimates in 2019 showing over 8.5 million individuals living with PD. Disability and death due to PD are increasing faster than for any other neurological disorder. Current estimates suggest that, in 2019,…
Read MoreGeneCode to Accelerate GDNF Mimetics program
Excellent start to the year 2022. GeneCode to Accelerate GDNF Mimetics program on Parkinson’s Disease with 2 million euro R&D Grant from Enterprise Estonia: PR_Genecode_EAS_EN_13.01.2022
Read MoreGeneCode and Argobio Partners
We are very honored to share the news of the GeneCode and Argobio Partners on Parkinson’s Disease in Argobio’s First Announced Research Agreement. Read more: https://www.argobiostudio.com/en/news/argobio-and-genecode-partner-on-parkinsons-disease-in-argobios-first-announced-research-agreement#news
Read More